iDose TR® Billing and Coding Support Guide

iDose TR® is a Procedural Pharmaceutical, Not a MIGS

iDose® TR (travoprost intracameral implant) 75 mcg

For a variety of patients with open angle glaucoma or ocular hypertension[1]

DRUG PAYMENT
J7355

+

FACILITY PAYMENT
0660T

+

PROFESSIONAL PAYMENT
0660T

New J-code for iDose TR®, J7355, effective July 1, 2024

Important Codes to Know

HCPCS Code J7355
Injection, travoprost, intracameral implant, 1 microgram, iDose TR is 75 mcg; **bill for 75 units**

CPT®* Code 0660T
Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach

ICD 10 Code examples, Open-angle glaucoma
H40.XXXX
H40.111X
Code specific to the individual patient's clinical condition

ICD 10 Code examples, Ocular hypertension
H40.051x
Code specific to the individual patient's clinical condition

Coverage and Reimbursement Considerations

Medicare Part B with a supplemental (i.e. Medigap) and/or secondary (i.e. commercial, Medicaid, Tricare) insurance may help cover additional out of pocket costs.

iDOSE TR® EXTENDS ACROSS THE SPECTRUM OF GLAUCOMA, STANDALONE OR COMBO-CATARACT



INDICATIONS AND USAGE
iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

IMPORTANT SAFETY INFORMATION

Dosage and Administration
For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications
iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings and Precautions
iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions
In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Please See Full Prescribing Information.
You are encouraged to report all side effects to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

Ordering Information
Order # G2-TR
iDose TR NDC (4-4-2 format): 25357-100-01
iDose TR NDC (5-4-2 format): 25357-0100-01
Ph 1-800-GLAUKOS (452-8567)
F 949.367 9838
customerservice@glaukos.com

iDose® *TR*